SUMMARY The clinical and microbiological outcome of the treatment of 94 men for uncomplicated non-gonococcal urethritis (NGU) was studied. Rosaramicin 250 mg six hourly for seven days was given to 46 men and tetracycline 250 mg six hourly for seven days to 48 men; the follow-up period was up to six weeks. Complete resolution of the clinical signs of infection was seen in 40 (87%) of the men treated with rosaramicin and in 37 (77%) of those treated with tetracycline. Chlamydia trachomatis was eliminated from 17 of the 18 men treated with rosaramicin and from all of the 16 men treated with tetracycline. Ureaplasma urealyticum was eliminated from 12 of the 14 men treated with rosaramicin and from 15 of the 19 receiving tetracycline. Clinical recovery correlated well with the elimination of C trachomatis but less well with that of U urealyticum. The two antimicrobial agents were equally effective in the therapy of NGU, but gastrointestinal side effects were significantly more common in men treated with rosaramicin.
Introduction
Non-gonococcal urethritis (NGU) is one of the commonest sexually transmitted diseases. There is a substantial body of evidence from isolation studies, serology, and response to antimicrobial therapy to indicate that Chlamydia trachomatis causes 35-60%7o of cases.
I
The evidence implicating Ureaplasma urealyticum is less compelling, but this organism is believed to cause some cases.2 At least one-quarter of NGU infections are of unknown aetiology.
Many years ago, empirical studies clearly showed that the tetracylines were clinically highly effective in the treatment of NGU.3 These agents show in-vitro activity against C trachomatis and against many strains of U urealyticum, and studies of men with NGU treated with tetracyclines have linked clinical improvement with the eradication of one or both of these organisms. 4 Patients with NGU who harbour neither C trachomatis nor U urealyticum show the poorest clinical response to treatment. 5 The macrolide antibiotic, erythromycin, also gives good results in the treatment of NGU. Its in-vitro activity against C trachomatis is reflected by its efficacy in chlamydiapositive NGU, and it also gives good results in chlamydia-negative NGU.6 It is active in vitro against many strains of U urealyticum, but its clinical efficacy against this organism has not been studied.
Rosaramicin is a macrolide antibiotic which is active against Neisscria gonorrhoeae and has given good clinical results in the treatment of gonorrhoea.7 It is also active against both C trachomatis and U urealyticum. Good results have been obtained in the treatment of both chlamydia-positive and chlamydianegative NGU8; its efficacy against U urealyticum associated with NGU has not yet been studied. In this investigation rosaramicin was compared with tetracycline in the treatment of NGU with regard to its clinical efficacy and action against C trachomatis and U urealyticum.
Patients and methods

CLINICAL PROCEDURES
A group ofmen with uncomplicated NGU was studied. The criteria for inclusion in the investigation were: (1) the presence of a visible urethral discharge; (2) a Gram stain of the discharge showing no intracellular diplococci and > 5 polymorphonuclear leucocytes (PMNL) per high-power field at x 1000 magnification; (3) negative culture result of this material for N gonorrhoeae; (4) no antibiotic treatment for four weeks before enrolment; and (5) no clinical evidence of serious systemic disease nor history of allergy to tetracyclines or macrolides. Informed consent to the investigation was obtained from each patient.
At first attendance, a history was taken and the patient fully examined. Specimens were collected as follows: (1) urethral material was collected with a plastic loop (Nunc Products Ltd) and spread on a glass slide for Gram staining; (2) a second specimen was used to inoculate a culture plate for N gonorrhoeae; (3) an endourethral wire-mounted cottonwool swab (Medical Wire and Equipment Co) was passed 1-2 cm into the urethra, removed, and cut off into a tube of mycoplasma transport medium; (4) a second wiremounted swab was passed 4-5 cm into the urethra, removed, and cut off into a tube of chlamydia transport medium; (5) in a two-glass urine test suspended material in the first glass was examined microscopically for PMNL and the midstream specimen examined for albumin and sugar and cultured for urinary pathogens; and (6) blood was collected for serological tests for syphilis, routine haematology, and blood chemistry.
TREATMENT ALLOCATION After a diagnosis of NGU had been made the patients were assigned by random numbers to two treatment schedules: rosaramicin 250 mg six hrly for seven days or tetracycline 250 mg six hrly for seven days. Followup examinations were performed on all patients on the completion of treatment (day 7) and two weeks after (day 21); when possible, a third follow-up examination was performed four weeks later (day 49). On each occasion after clinical examination specimens (1) to (S) were examined as described above. Serological tests for syphilis, if initially giving negative results, were not repeated during the study, and haematological and biochemical tests were repeated only on day 7 . Neither the patient nor the physician knew which drug had been taken, and the data were evaluated blindly. The two treatment groups were similar for demographic data and previous history of STD. with tetracycline (in nine as the sole pathogen and in seven in association with U urealyticum). Chlamydia were not reisolated from any of these patients during the follow-up period (table II) . Differences in responses between those given rosaramicin and those given tetracycline were not significant. 
